Pirfenidone

A speaker at the PFF Summit highlighted recent trials and therapeutic updates for progressive fibrosing interstitial lung disease.

In this video from ACR Convergence 2021, Jeffrey A. Sparks, MD, MMSc, associate physician at Brigham and Women's Hospital, discusses results from the TRAIL1 trial in which pirfenidone did not meet its primary endpoints.

This week, the FDA approves single-use bronchoscopes; a study finds the Moderna COVID-19 vaccine is safe and effective in adolescents; CMS nixes the most-favored nation pricing model for Medicare Part B; and more.

Adoption of pirfenidone and nintedanib for the treatment of idiopathic pulmonary fibrosis has been low in the U.S., according to an analysis published in the Annals of the American Thoracic Society.

Pirfenidone vs. placebo in patients with HF, EF at least 45% and elevated natriuretic peptide levels.

In patients with idiopathic pulmonary fibrosis, antifibrotic treatment may reduce the risk for all-cause mortality and acute exacerbations, according to a systematic review and meta-analysis published in Chest.

In patients with idiopathic pulmonary fibrosis, pirfenidone delayed new-onset respiratory adverse events and antibiotic prescriptions, but did not delay new prescription of concomitant antitussive drugs compared with placebo.

In patients with HF with preserved ejection fraction, pirfenidone was associated with reduction in myocardial fibrosis compared with placebo, according to a presentation at the American College of Cardiology Scientific Session.